异柠檬酸脱氢酶2(IDH2)R172突变急性髓系白血病的治疗
针对IDH2R172突变急性髓系白血病,英国试验早期报告年轻成人患者预后极差,但德国-奥地利AML研究组未证实。本研究调查 later 队列的IDH2突变患者,发现 later 试验中IDH2R172突变AML预后改善,数据提示可能与更多使用异基因移植巩固首次缓解有关。
要点
- 英国早期试验中IDH2R172突变年轻AML患者预后极差,但德国-奥地利研究组未 corroborate。
- Later 试验中IDH2R172突变AML预后改善。
- 数据提示预后改善可能与更多使用异基因移植巩固首次缓解有关。
核心结论
- Later 试验中IDH2R172突变AML预后改善,数据提示可能与增加异基因移植巩固首次缓解的使用有关。
研究设计与样本
- 研究调查了 later 队列的IDH2突变患者,以识别结局变化并探讨是否可指导IDH2R172 AML的最佳治疗。
主要发现
- Later 试验中IDH2R172突变AML的结局改善。
- 数据提示结局改善可能与更多使用异基因移植巩固首次缓解有关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although we earlier reported a very poor outcome for younger adult patients with isocitrate dehydrogenase 2 (IDH2)R172 -mutated acute myeloid leukaemia (AML) entered into UK trials compared to IDH2WT and IDH2R140 -mutated patients, this was not corroborated by a study from the German-Austrian AML Study Group. We have therefore investigated a later cohort of IDH2-mutated patients to identify any changes in outcome and whether this could inform the optimal treatment for IDH2R172 AML. We found an improved outcome for IDH2R172 -mutated AML in the later trials and the data suggests that this may be due to the increased use of allogeneic transplantation to consolidate first remission.
引用
- Linch DC, Hills RK, Burnett AK, et al. Therapy for isocitrate dehydrogenase 2 (IDH2)R172 -mutant acute myeloid leukaemia. Br J Haematol. 2021. PMID: 34870324. doi:10.1111/bjh.17981
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。